Trading At Over Twice The 52 Week Low, Affimed NV (Nasdaq:AFMD) Close At $3.31

Affimed NV (Nasdaq:AFMD)

October 11th, 2018

Amidst falling markets Affimed NV fell $0.10 Saturday which equals a 2.79% drop, closing at $3.31. While the stock did drop today, remember that it is still trading at 188% of its 52 week low of $1.15. In addition to the stock finishing lower, the trading volumes were only 44% of normal which could be an indication of investor uncertainty. Be aware that the Piotroski Score1 is calculated to be 2, which is very low as the scale goes from 0-9. This is considered to be a weak score in terms of financial strength.

AFMD was outperformed by the rest of the Healthcare sector which went down just 2.66%.

Market Sectors

Thursday saw a downward swing in all sectors of the market with Energy seeing the biggest drop at 3.09% drop. Healthcare has seen the biggest year-to-date gain at 12%. The biggest loss this year has been the Materials sector dropping 10%.

Utilities saw a turn around from its 5-day performance of 2.79% trading down 1.97%.

Sector Breakdown

  • Communication Services went down with a -0.84% change.
  • Materials went down with a -1.20% change.
  • Information Technology went down with a -1.27% change.
  • Consumer Discretionary went down with a -1.70% change.
  • Utilities went down with a -1.97% change.
  • Industrials went down with a -2.28% change.
  • Consumer Staples went down with a -2.32% change.
  • Healthcare went down with a -2.66% change.
  • Real Estate went down with a -2.91% change.
  • Financials went down with a -2.93% change.
  • Energy went down with a -3.09% change.

Affimed NV Info

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company’s products include AFM24, a NK-cell bispecific antibody targets EGFR-wild type represents a validated antigen expressed by various solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

All amounts in USD unless otherwise indicated

(1) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Affimed NV’s score is ), and 9 is the best.

AFMD daily update
AFMD daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.